Plourde PV - Search Results

1

Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.

Vrooman LM, Kirov II, Dreyer ZE, Kelly M, Hijiya N, Brown P, Drachtman RA, Messinger YH, Ritchey AK, Hale GA, Maloney K, Lu Y, Plourde PV, Silverman LB. Vrooman LM, et al. Among authors: plourde pv. Pediatr Blood Cancer. 2016 Feb;63(2):228-33. doi: 10.1002/pbc.25757. Epub 2015 Sep 16. Pediatr Blood Cancer. 2016. PMID: 26376459 Free PMC article. Clinical Trial.

2

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP. Salzer WL, et al. Blood. 2013 Jul 25;122(4):507-14. doi: 10.1182/blood-2013-01-480822. Epub 2013 Jun 5. Blood. 2013. PMID: 23741010 Free PMC article. Clinical Trial.

3

Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.

Plourde PV, Jeha S, Hijiya N, Keller FG, Silverman LB, Rheingold SR, Dreyer ZE, Dahl GV, Mercedes T, Lai C, Corn T. Plourde PV, et al. Pediatr Blood Cancer. 2014 Jul;61(7):1232-8. doi: 10.1002/pbc.24938. Epub 2014 Jan 16. Pediatr Blood Cancer. 2014. PMID: 24436152 Free article. Clinical Trial.

4

Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.

Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP. Salzer WL, et al. Among authors: plourde pv. Ann N Y Acad Sci. 2014 Nov;1329:81-92. doi: 10.1111/nyas.12496. Epub 2014 Aug 5. Ann N Y Acad Sci. 2014. PMID: 25098829 Free article. Review.

5

A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.

Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. Buzdar AU, et al. Cancer. 1997 Feb 15;79(4):730-9. Cancer. 1997. PMID: 9024711 Clinical Trial.

6

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A. Plourde PV, et al. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):175-9. doi: 10.1016/0960-0760(95)00045-2. J Steroid Biochem Mol Biol. 1995. PMID: 7626450 Review.

7

Arimidex: a potent and selective fourth-generation aromatase inhibitor.

Plourde PV, Dyroff M, Dukes M. Plourde PV, et al. Breast Cancer Res Treat. 1994;30(1):103-11. doi: 10.1007/BF00682745. Breast Cancer Res Treat. 1994. PMID: 7949201

8

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Buzdar A, et al. Among authors: plourde pv. J Clin Oncol. 1996 Jul;14(7):2000-11. doi: 10.1200/JCO.1996.14.7.2000. J Clin Oncol. 1996. PMID: 8683230 Clinical Trial.

9

Aromatase inhibitors in metastatic breast cancer.

Buzdar AU, Plourde PV, Hortobagyi GN. Buzdar AU, et al. Among authors: plourde pv. Semin Oncol. 1996 Aug;23(4 Suppl 9):28-32. Semin Oncol. 1996. PMID: 8824462

10

ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.

Buzdar AU, Jonat W, Howell A, Plourde PV. Buzdar AU, et al. Among authors: plourde pv. J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):145-9. J Steroid Biochem Mol Biol. 1997. PMID: 9365184 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

21 results

Search Page